利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

80 条记录 (耗时 0.035 秒)

    METHODS AND COMPOSITIONS FOR DIAGNOSING RENAL CELL CARCINOMA
    3.
    发明申请
    METHODS AND COMPOSITIONS FOR DIAGNOSING RENAL CELL CARCINOMA 审中-公开

    公开(公告)号：WO2018100190A1

    公开(公告)日：2018-06-07

    申请号：PCT/EP2017/081255

    申请日：2017-12-01

    申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS-SUD

    发明人： EID, Pierre ,  AZZI-HATEM, Sandy

    IPC分类号： G01N33/574

    摘要： The present invention relates to a method for diagnosing renal cell carcinoma (RCC) in a subject comprising the steps of: i) measuring the expression level of soluble SEMA7A in a fluid sample; ii) comparing the expression measured at step i) with its predetermined reference value, and iii) concluding that the subject suffers from RCC when the expression level of SEMA7A is higher than its predetermined reference value. Inventors found that SEMA7A was detected in all patients despite the disease ontogeny. SEMA7A levels were significantly reduced in patients one month after nephrectomy, and almost inexistent in healthy donors. This reinforces the specific correlation of SEMA7A to renal cell carcinoma. More importantly, SEMA7A was detected in all grades IV of RCC at similar levels, suggesting that it could be an early stage biomarker. Taken altogether, these data define SEMA7A as an early circulating biomarker of renal cell carcinoma, allowing early diagnosis in a non-invasive manner.

    NANOPARTICULATE PRODRUGS
    5.
    发明申请
    NANOPARTICULATE PRODRUGS 审中-公开
    纳米粒子前药

    公开(公告)号：WO2018054953A1

    公开(公告)日：2018-03-29

    申请号：PCT/EP2017/073740

    申请日：2017-09-20

    申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITÉ PARIS-SUD 11

    发明人： FATTAL, Elias ,  TSAPIS, Nicolas ,  LORSCHEIDER, Mathilde ,  CANIONI, Romain ,  REYNAUD, Franceline

    IPC分类号： A61K9/51 ,  A61K31/573

    摘要： The present invention relates to anti-inflammatory drug formulation. Especially, this invention relates to corticosteroid prodrug nanoparticle. In a first aspect, this invention relates to a nanoparticle comprising a therapeutic agent and a surface coating material. The invention also relates to a process of manufacturing at least one nanoparticle of invention. The invention also relates to pharmaceutical composition and pharmaceutical kits.

    摘要翻译： 本发明涉及抗炎药物制剂。 特别地，本发明涉及皮质类固醇前药纳米颗粒。 在第一方面，本发明涉及包含治疗剂和表面涂层材料的纳米颗粒。 本发明还涉及制造至少一种本发明纳米颗粒的方法。 本发明还涉及药物组合物和药物试剂盒。

    ANTI-ANTITHROMBIN SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF
    6.
    发明申请
    ANTI-ANTITHROMBIN SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF 审中-公开
    抗反应性单克隆抗体及其含有多肽的抗体

    公开(公告)号：WO2017158176A1

    公开(公告)日：2017-09-21

    申请号：PCT/EP2017/056424

    申请日：2017-03-17

    申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS-SUD

    发明人： LENTING, Peter ,  DENIS, Cécile ,  CHRISTOPHE, Olivier ,  AYME, Gabriel

    IPC分类号： C07K16/38 ,  A61K39/00

    CPC分类号： C07K16/36 ,  A61K38/1725 ,  A61K2039/505 ,  A61K2039/507 ,  A61P7/04 ,  C07K14/472 ,  C07K16/38 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31 ,  C12N15/62

    摘要： The present invention relates to isolated single-domain antibodies (sdAb) directed against Antithrombin (AT) to prolong the half-life of the proteins. Inventors have generated isolated single domain antibodies (sdAbs) directed against antithrombin. They observed that in amidolytic assays, sdAbs are incapable of blocking the inhibitory antithrombin activity towards thrombin and factor Xa in the presence of heparin. The different combinations of sdAb were able to block the inhibitory antithrombin activity towards thrombin and factor Xa in mice. Thus, the inventors propose to use different combinations of sdAb to block the inhibitory function of antithrombin in order to promote thrombin generation and thus treat haemophilia and other conditions that are associated with bleeding. Accordingly, the invention relates also to a method of preventing or treating bleeding disorders in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of the single domain antibodies or the drug conjugate of the invention.

    摘要翻译： 本发明涉及针对抗凝血酶（AT）以延长蛋白质半衰期的分离的单域抗体（sdAb）。 发明人已经产生针对抗凝血酶的分离的单域抗体（sdAb）。 他们观察到，在酰胺分解测定中，sdAb在肝素存在下不能阻断对凝血酶和因子Xa的抑制性抗凝血酶活性。 sdAb的不同组合能够阻断小鼠中对凝血酶和因子Xa的抑制性抗凝血酶活性。 因此，发明人建议使用不同的sdAb组合来阻断抗凝血酶的抑制功能，以促进凝血酶的产生，从而治疗与出血有关的血友病和其他病症。 因此，本发明还涉及预防或治疗有需要的受试者的出血性疾病的方法，其包括向所述受试者施用治疗有效量的本发明的单域抗体或药物缀合物。